Cite
HARVARD Citation
Karakas, M. et al. (2022). Single-dose of adrecizumab versus placebo in acute cardiogenic shock (ACCOST-HH): an investigator-initiated, randomised, double-blinded, placebo-controlled, multicentre trial. Lancet. 10 (3), pp. 247-254. [Online].